Logo image of ADPT

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

NASDAQ:ADPT - Nasdaq - US00650F1093 - Common Stock - Currency: USD

7.9  +0.01 (+0.13%)

After market: 7.9 0 (0%)

Fundamental Rating

2

Overall ADPT gets a fundamental rating of 2 out of 10. We evaluated ADPT against 55 industry peers in the Life Sciences Tools & Services industry. ADPT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ADPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADPT had negative earnings in the past year.
In the past year ADPT has reported a negative cash flow from operations.
ADPT had negative earnings in each of the past 5 years.
ADPT had a negative operating cash flow in each of the past 5 years.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

The Return On Assets of ADPT (-29.57%) is worse than 74.55% of its industry peers.
With a Return On Equity value of -78.68%, ADPT is not doing good in the industry: 76.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -29.57%
ROE -78.68%
ROIC N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

With a decent Gross Margin value of 59.72%, ADPT is doing good in the industry, outperforming 80.00% of the companies in the same industry.
In the last couple of years the Gross Margin of ADPT has declined.
ADPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADPT has been increased compared to 1 year ago.
ADPT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADPT is higher compared to a year ago.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ADPT has an Altman-Z score of -1.50. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.50, ADPT is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.65 indicates that ADPT is somewhat dependend on debt financing.
ADPT has a worse Debt to Equity ratio (0.65) than 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z -1.5
ROIC/WACCN/A
WACC10.49%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.89 indicates that ADPT has no problem at all paying its short term obligations.
ADPT has a Current ratio (2.89) which is comparable to the rest of the industry.
A Quick Ratio of 2.81 indicates that ADPT has no problem at all paying its short term obligations.
ADPT has a Quick ratio of 2.81. This is comparable to the rest of the industry: ADPT outperforms 54.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.81
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.01%, which is quite impressive.
Looking at the last year, ADPT shows a small growth in Revenue. The Revenue has grown by 5.09% in the last year.
ADPT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.03% yearly.
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
Revenue 1Y (TTM)5.09%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%3.66%

3.2 Future

The Earnings Per Share is expected to grow by 17.76% on average over the next years. This is quite good.
Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 19.31% on average per year.
EPS Next Y13.67%
EPS Next 2Y16.02%
EPS Next 3Y17.76%
EPS Next 5YN/A
Revenue Next Year19.69%
Revenue Next 2Y20.87%
Revenue Next 3Y22.19%
Revenue Next 5Y19.31%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADPT's earnings are expected to grow with 17.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.02%
EPS Next 3Y17.76%

More info and screens

0

5. Dividend

5.1 Amount

ADPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (4/25/2025, 8:00:00 PM)

After market: 7.9 0 (0%)

7.9

+0.01 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners94.45%
Inst Owner Change0.14%
Ins Owners2.19%
Ins Owner Change-0.01%
Market Cap1.17B
Analysts82.86
Price Target10.03 (26.96%)
Short Float %7.04%
Short Ratio4.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.49%
Min EPS beat(2)12%
Max EPS beat(2)24.98%
EPS beat(4)4
Avg EPS beat(4)12.79%
Min EPS beat(4)5.24%
Max EPS beat(4)24.98%
EPS beat(8)6
Avg EPS beat(8)7.96%
EPS beat(12)10
Avg EPS beat(12)10.22%
EPS beat(16)14
Avg EPS beat(16)11.64%
Revenue beat(2)2
Avg Revenue beat(2)7.15%
Min Revenue beat(2)1.07%
Max Revenue beat(2)13.22%
Revenue beat(4)4
Avg Revenue beat(4)7.41%
Min Revenue beat(4)1.07%
Max Revenue beat(4)13.22%
Revenue beat(8)6
Avg Revenue beat(8)1.99%
Revenue beat(12)8
Avg Revenue beat(12)1.2%
Revenue beat(16)12
Avg Revenue beat(16)4.87%
PT rev (1m)1.72%
PT rev (3m)29.67%
EPS NQ rev (1m)0.43%
EPS NQ rev (3m)-7.83%
EPS NY rev (1m)0.65%
EPS NY rev (3m)1.2%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-8.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.56
P/FCF N/A
P/OCF N/A
P/B 5.79
P/tB 14.62
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS1.2
BVpS1.36
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.57%
ROE -78.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.72%
FCFM N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.03%
Cap/Sales 2.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.81
Altman-Z -1.5
F-Score4
WACC10.49%
ROIC/WACCN/A
Cap/Depr(3y)48.38%
Cap/Depr(5y)161.41%
Cap/Sales(3y)5.71%
Cap/Sales(5y)15.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
EPS Next Y13.67%
EPS Next 2Y16.02%
EPS Next 3Y17.76%
EPS Next 5YN/A
Revenue 1Y (TTM)5.09%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%3.66%
Revenue Next Year19.69%
Revenue Next 2Y20.87%
Revenue Next 3Y22.19%
Revenue Next 5Y19.31%
EBIT growth 1Y22.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.37%
EBIT Next 3Y26.5%
EBIT Next 5YN/A
FCF growth 1Y40.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.09%
OCF growth 3YN/A
OCF growth 5YN/A